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Abstract
In December 2019, the surfacing and spread of a novel coronavirus, SARS-CoV2, resulted in the global COVID-19 pandemic. As a viral antigen, SARS-CoV-2 poses a
particular threat to the obstetric population due to physiological and immunological
changes that women face during pregnancy. While recent studies have found that SARSCoV-2 may have better clinical outcomes as compared to other betacoronaviruses,
adverse pregnancy events such as ICU admission, preeclampsia, and/or preterm birth
have been associated with COVID-19. Progress has been made in better understanding
the pathophysiology of SARS-CoV-2 in pregnancy, but there is still much to be known
about the interaction between the two conditions. As SARS-CoV-2 spreads largely
through asymptomatic and pre-symptomatic carriers, serological surveys of the virus help
us better understand the actual transmission rates and can also provide important
information about the mechanisms of the humoral immune response. These antibody
specific studies of SARS-CoV-2 are of particular interest to the obstetric population as
inclusion of umbilical cord serum allows researchers to gain insight on vertical
transmission, or the maternal-fetal transfer of antibodies across the placenta. As a
neonate’s immune defense system is dependent on the immune cells it receives from its
mother, the potential for vertical transmission of SARS-CoV-2 antibodies is critical as
the pandemic continues. Using data from serological experiments carried out at the
University of Massachusetts Chan Medical School and its partnering Memorial Medical
Center, this study further investigates antibody levels in the umbilical cord blood across
various clinical factors in the mother. Cord blood RBD IgG antibody levels did not
significantly vary from antibody levels of nonpregnant individuals, nor were they
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impacted by diagnosis of preeclampsia. A strong correlation was found between trimester
of maternal SARS-CoV-2 infection and neonatal antibody levels with second trimester
infections resulting in higher levels. The results of this study have significant
implications for SARS-CoV-2 infection in the obstetric population with the potential to
impact best vaccine administration practices.

Introduction
As this paper investigates SARS-CoV-2 antibody levels in the obstetric
population, the introduction will provide an overview on three main sections: SARSCoV-2 and the COVID-19 pandemic, COVID-19 and pregnancy, and seroprevalence of
COVID-19 in the obstetric population. The first section will discuss the origins of SARSCoV-2, compare the novel coronavirus to other viruses in the Coronaviridae family, and
explain viral transmission. The second section will outline the potential threat of COVID19 to pregnant women and the results of preliminary studies in the field. The final section
will explain serological surveys, the benefits they provide during viral outbreaks, and
how they can inform studies of maternal-fetal transfer across the placenta. Together,
these topics are essential in understanding the serological analyses of umbilical cord
blood that were conducted in this thesis project.

SARS-CoV-2 and the COVID-19 Pandemic
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged as a
novel coronavirus in 2019 and has since spread rapidly across the globe resulting in the
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coronavirus disease-19 (COVID-19) pandemic. As of January 12th, 2022, the COVID-19
pandemic has resulted in 312.2 million infections and 5.5 million associated deaths
(WHO, 2021d). SARS-CoV-2 stands out from other coronaviruses due to its robust
ability to transmit through pre-symptomatic and asymptomatic carriers which allows it to
transfer undetected and spread in a seemingly uncontrollable manner. The virus was
originally discovered in Wuhan, China in December of 2019 due to an outbreak linked to
a seafood and wildlife market. By January 5th, the complete genome of the virus was
sequenced, and it was classified as a betacoronavirus within the Coronaviridae family
(Lofti et al., 2020). SARS-CoV-2, unnamed at the time, was officially identified as the
causative agent of the outbreak in Wuhan on January 7th. Less than a week later, cases
began to appear in countries across Asia and, by January 20th, 2020, the first confirmed
case of COVID-19 was reported in the United States (CDC, 2021c).
There are seven other known viruses in the Coronaviridae family that are capable
of human infection including SARS-CoV-2 (Table 1; Wang et al., 2021). The
Coronaviridae family is characterized by large, positive-sense, single-stranded RNA
viruses that have long spike proteins that typically range from 16–21 nm. In fact, the
family consists of the largest known RNA viruses (Payne, 2017). Including SARS-CoV2, all known coronaviruses that can result in human infection have been identified as
zoonotic viruses meaning that they originated in a different animal species and eventually
infected humans (Zhang & Holmes, 2020). In the case of known coronaviruses, all
studies have pointed to bats as the specific species of origin (Hamady et al., 2021).
Among the seven human coronaviruses, four have low pathogenicity (229E, NL63,
OC43, and HKU1), referred to as HCoVs, and three are highly pathogenic (SARS-CoV,
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MERS-CoV, and SARS-CoV-2; Azkur et al., 2020). Infection of one of the low
pathogenic coronaviruses results in mild, cold-like symptoms. These viruses are
seasonally-circulated like the common flu and have been classified as endemic in humans
(Wang et al., 2021). SARS-CoV, MERS-CoV, and SARS-CoV-2 all result in more
severe symptoms and outcomes such as fever,
cough, shortness of breath in addition to cold-like symptoms. All three of the more

Table 1. A comparison A comparison of clinical and non-clinical characteristics of
coronaviruses SARS-CoV, MERS, HCoVs, and SARS-CoV-2 (Hamady et al., 2021).
pathogenic coronaviruses belong to the same genus, betacoronavirus, and are known to
cause respiratory infections and can lead to death (Wang et al., 2021). Genome-wide
studies have also found that SARS-CoV and MERS have ~79.5% and 51% sequence
similarity to the protein-coding regions of SARS-CoV-2 respectively (Lofti et al., 2020).
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Due to similar symptomatology, their shared genus, and high percentages of genome
similarity, many early studies use previous knowledge of SARS-CoV and MERS to guide
research on SARS-CoV-2.
SARS-CoV, or Severe Acute Respiratory Syndrome Coronavirus, first emerged
as an abnormal case of pneumonia in November 2002 in the Guangdong Province of
China. In February 2003, after similar cases also appeared in Vietnam and Hong Kong,
SARS-CoV was officially identified as a betacoronavirus (CDC, 2021c). Originating
from bat species, SARS-CoV was found to have an intermediary host of Himalayan palm
civets which were commonly farmed in Southern China (Payne, 2017). Although
spreading to 29 countries across five continents and resulting in 774 deaths globally,
SARS-CoV was confined within the year and maintained its status as an epidemic
(WHO, 2021b). In January of 2004, the CDC issued the “Notice of Embargo of Civets”
which banned the importation of civets of any kind into the United States which is still in
effect today (CDC, 2021c).
MERS, or the Middle Eastern Respiratory Syndrome coronavirus, was discovered
in 2012 in several Middle Eastern countries. The virus was identified as having an
intermediary host of dromedary camels (Hamady et al., 2021). MERS can be transmitted
from camel to camel, camel to human, or human to human when in close contact. Since
2012, there have been 2578 confirmed cases of MERS resulting in 888 deaths globally
(WHO, 2021a). MERS was not contained as quickly as SARS, but it is slightly less
widespread geographically with only 27 countries reporting cases outside of the Eastern
Mediterranean Region – which reported cases in 12 countries. Although case counts have
generally decreased since peak infection rates in 2014, the virus remains prevalent

Rose 7

globally and particularly in Saudi Arabia where cases remained well over 100 until 2020
(WHO, 2021e). A breakthrough peak in 2019 resulted in 204 cases in Saudi Arabia alone,
but since then case numbers have universally declined with only 11 cases in Saudi Arabia
and 14 cases globally in 2021 (WHO, 2021e).
Relative to SARS-CoV and MERS, two clear distinctions in SARS-CoV-2 have
quickly emerged: lower mortality and higher morbidity rates. SARS-CoV and MERS
both have higher mortality rates of approximately 10% and 35% respectively (Henss et
al., 2021 and Wang et al., 2021). The mortality rate of SARS-CoV-2 remains at
approximately 2% globally although it appears to be lowering with the Omicron variant
which recently emerged (Petrosillo et al., 2020). Relatedly, the reproductive number (R0)
of SARS-CoV-2 is higher than both SARS and MERS, but more so for the latter. R0
values serve as a measure of disease transmissibility or contagiousness as a function of
the biological character of a pathogen and human behavior. In short, the reproductive
number represents the estimated number of patients likely to become infected from an
individual COVID+ patient and can serve as a measure of morbidity. R0 values are
particularly important when diseases result in epidemics or pandemics, such as the
COVID-19 pandemic, as they are crucial in understanding the necessary precautions
needed to stop the spread. For example, government mandated quarantines and the scope
of contact tracing are often based on R0 values (Achaiah et al., 2020). Previous studies
have found that MERS and SARS have average R0 values of < 1 and 1.7-1.9 respectively
(Petrosillo et al., 2020). Comparably, although an exact SARS-CoV-2 R0 value is still
controversial and under consideration, a meta-analysis conducted in February 2020 by
Liu et al. found a R0 range of 1.5-6.68 across 12 studies with median and mean R0 values
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coming out to be 2.79 and 3.28 respectively (Liu et al., 2020a). In a similar study
conducted by Park et al. in February 2020, the authors found that 13 out of 20 studies
observed yielded a SARS-CoV-2 R0 within a range of 2 and 3 (Park et al., 2020).
Therefore, most individuals who have contracted SARS-CoV-2 are expected to transmit
the virus to 2 to 3 additional people. Although the variant is relatively new and the R0 of
the omicron variant is still under review, the rapid increase of infection rates across the
globe suggest that omicron is even more contagious than previous variants.
The increased morbidity and decreased mortality in SARS-CoV-2 relative to
SARS-CoV and MERS, in addition to the significant prevalence of pre-symptomatic and
asymptomatic carriers, has resulted to the rapid transmission and exponential rise in
COVID cases globally. Pre-symptomatic carriers are capable of transmitting the virus
prior to experiencing symptoms. The exact definition of pre-symptomatic patients varies
slightly across studies which has resulted in slightly varied results. In a study conducted
by He et al. in July 2021, the authors defined pre-symptomatic carriers as patients who
are asymptomatic at the time of their COVID diagnosis, but then went on to develop
symptoms later on. With this definition, He et al. found that the pooled percentage of presymptomatic patients from 10 articles published between March and May 2020 was
48.9% with a 95% confidence interval range of 31.6%-66.2% (He et al., 2021).
Meyerowitz et al. conducted a study in June 2021 that used the same definition of presymptomatic carriers but found a slightly lower percentage range for pre-symptomatic
patients of 25-40% (Meyerowitz et al., 2021). While both He et al. and Meyerowitz et
al.’s meta-analyses represented studies from across the globe, He et al.’s study included
primarily studies from China and other Asian countries whereas Meyerowitz et al.’s
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study primarily represented American studies. The definition of asymptomatic carriers is
more universal as it encompasses all patients who are diagnosed with COVID but never
experience symptoms throughout the course of their infection. He et al. and Meyerowitz
et al. both investigated asymptomatic carriers as well and found pooled asymptomatic
proportions of 15.6% and 17%-20% respectively. While asymptomatic spread is possible
for SARS-CoV and MERS as well, previous studies have found that it is less prevalent as
more than 90% of infected patients experienced symptoms for both SARS-CoV and
MERS (Wilder-Smith et al., 2005 and Al-Tawfiq, 2020).
SARS-CoV-2 is primarily transmitted from human-to-human through the
respiratory droplets (>5-10 μm in diameter) of an infected individual. Early studies found
that the respiratory droplets typically dissipate quickly and traverse up to ~6 feet (Lofti et
al., 2020). The virus can also remain intact in aerosolized droplets (<5 μm in diameter)
and is capable of remaining in the air for approximately three hours. Airborne inhalation
is the most common mode of transmission and is possible from respiratory droplets of all
sizes. However, transmission through contact with contaminated surfaces is also possible
and takes place when the larger respiratory droplets, which are capable of settling before
evaporation, land on surfaces within 6 feet of an infected individual (Prather et al., 2020).
Droplets are most efficiently spread through coughing or sneezing, but can also be spread
simply from speaking or breathing. Initial infection typically occurs when the
contaminated droplets make contact with the mucous membranes of a healthy
individual’s eyes, nose, or mouth (Lofti et al., 2020). For this reason, social distancing
precautions and mask mandates are implemented as some of the main modes of defense
against SARS-CoV-2 transmission.
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COVID-19 and Pregnancy
Novel viral antigens such as SARS-CoV-2 are of particular concern in the
obstetric population due to the physiological changes that women face throughout their
pregnancy that can contribute to a shift in their immune systems away from a proinflammatory response. This increased risk of morbidity along with the potential of
negative fetal impact in pregnant women places the obstetric population on the list of
vulnerable populations as the pandemic surges on. Previous studies specifically on
respiratory viral infections (SARS-CoV, MERS, and the influenza viruses) have found
that infected pregnant women are more likely to develop critical disease and have
perinatal complications (Chen, G et al., 2021). Increased mortality rates are often
observed in pregnant patients infected with SARS-CoV and MERS as well (Fathi et al.,
2020). The study of SARS-CoV-2 infection in the obstetric population has been
prioritized to better understand the impact of the virus during pregnancy and to determine
whether the virus causes similar outcomes in pregnant women to those observed in SARS
and MERS. Just over two years after the virus was identified, a variety of studies on the
effect of COVID-19 on pregnancy have been published. However, there is still
uncertainty in the pathophysiology of SARS-CoV-2 in pregnancy with a variety of
findings, many varying, and challenges associated with an evolving virus.
Through an early systematic review of the Center for Disease and Control’s
COVID-19 database from January 2020 – June 2020, Ellington et al. (2020) investigated
the discrepancies between pregnant and non-pregnant women of reproductive age (15
– 44 years of age). The authors found that of the cases where symptom status was
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reported, 97.1% of pregnant women and 96.9% of nonpregnant women were
symptomatic. These statistics remained consistent across most symptoms: cough and
shortness of breath whereas headache, muscle aches, fever, chills, and diarrhea were
reported with minimal difference across pregnant and nonpregnant women (Ellington et
al., 2020). One of the most substantial findings of the study was the large difference in
hospitalization rates between the two populations. Of all reported COVID-19 cases in the
obstetric population, 31.5% resulted in a hospitalization compared to only 5.8% reported
within nonpregnant patients. Ellington et al. also found that, in addition to pregnant
patients being 5.4 times more likely to be hospitalized, they were also 1.5 times more
likely to be admitted to the ICU, and 1.7 times more likely to require mechanical
ventilation. However, the authors suggested that a possible explanation for the higher
rates of hospitalization in the obstetric population beyond pregnancy status could be the
implementation of universal screening that has become commonplace in labor and
delivery units. Finally, the authors found that there was no significant difference in
mortality rates among the two populations (Ellington et al., 2020).
Of particular interest in the study of SARS-CoV-2 in pregnancy is the possibility
of “vertical transmission” – the spread of a pathogen, in this case a SARS-CoV-2
infection, from the mother to the fetus or neonate. Within this definition vertical
transmission can take place during the antepartum, intrapartum, or even the postpartum
period if the neonate comes in contact with bodily fluid through the placenta in utero or
through breast milk while breastfeeding (Petrosillo et al., 2020). Vertical transmission is
frequent among several common pathogens that have been denoted as “TORCH”
pathogens, those that are currently monitored in the hospital course of all pregnancies.
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TORCH pathogens include Toxoplasma gondii, Other (Listeria monocytogenes,
Treponema pallidium, parvovirus, HIV, varicella zoster virus), Rubella,
Cytomegalovirus, and Herpesviruses type-1 and type-2. More recently, syphilis and the
Zika virus are also commonly included in this category of infections (Arora et al., 2017).
As antenatal fetal infections of these TORCH viruses are major contributors to morbidity
and mortality measures globally, monitoring for the viruses in both the mother and fetus
is crucial (Arora et al., 2017). While there is currently no guaranteed safeguard against
fetal infection, further precautions can be taken during the pregnancy course and delivery
of infected mothers to avoid vertical transmission.
Prior to the publication of studies on vertical transmission of SARS-CoV-2
specifically,
analyses of maternal-fetal transmission were revisited and newly conducted for both
SARS-CoV and MERS. Literature suggests that there was minimal to no evidence of
vertical transmission present in cases of mothers infected with SARS-CoV or MERS (Di
Mascio et al., 2020). These findings are promising as they suggest there may be a lack of
substantial vertical transmission with the infection of betacoronaviruses. Luckily, the
implications of previous literature were supported by the majority of initial studies on
maternal-fetal transmission of SARS-CoV-2 (Karimi-Zarchi et al., 2020, Schwartz, 2020,
and Cribiù et al., 2021). These findings suggest that the placenta likely serves as a
functional barrier between maternal and fetal infection. However, while most studies
show no evidence of vertical transmission whatsoever, some studies have observed
maternal-fetal transmission at low rates. In an early 2020 study conducted by Petrosillo et
al., the authors found that 13 out of 1287 neonates observed across 60 studies tested
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positive for COVID following delivery (~1%; Petrosillo et al., 2020). Therefore, while
vertical transmission of SARS-CoV-2 has been found to be highly unlikely, it is possible,
and it is important to continue to monitor the infection status of mothers and neonates for
the duration of the pandemic.
Preliminary
findings of COVID19 symptomatology
in women have also
led to further
research on SARSCoV-2 infections in
pregnant women

Figure 1. Diagnostic criteria for preeclampsia (Wagner,
2004).

relative to hypertensive disorders such as preeclampsia. Preeclampsia is a
hyperinflammatory condition that takes place during pregnancy and is characterized by
high blood pressure due to an overproduction of proinflammatory cytokines (Illi et al.,
2021). Preeclampsia is clinically defined as “the new onset of hypertension in pregnancy
after 20 weeks’ gestation with proteinuria in a previously normotensive woman” and it
affects 0.6-1.2% of pregnancies in the US (Society for Maternal-Fetal Medicine, 2013).
Preeclampsia refers to blood pressure that rises above 140/90 and proteinuria is
diagnosed when 0.3 grams or more of protein is detected in urine in a 24-hour collection
time. Preeclampsia can also be defined by elevated blood pressure with evidence of endorgan damage in the absence of proteinuria and can become severe when the
hypertensive metrics rise or other significant clinical factors are met (Figure 1; Wagner,
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2004). Early research on both preeclampsia and COVID-19 suggests that many of the
same pro-inflammatory cytokines that contribute to preeclampsia have been found to be
responsible for severe COVID-19-induced cytokine storms. Cytokine storms take place
when the body releases an abundance of cytokines in response to a pathogen and they
typically result in damage to organs or tissue death (Illi et al., 2021). Through further
investigation, Illi et al. identified that the renin angiotensin system (RAS), a hormonebased system that aids in blood pressure control, seemed to be a key link between SARSCoV-2 infection and preeclampsia as the presence of either results in uncommon levels of
expression of many central RAS components and hyperinflammation (Figure 2). The
authors also identified significant endothelial damage as an additional commonality (Illi
et al., 2021). These similarities observed at the cellular level prompted researchers to
further explore the relationship between SARS-CoV-2 and preeclampsia and their clinical
outcomes.
As complications such as premature birth, intrauterine growth restrictions, or
immune system defects are characteristic of preeclampsia, it is important to investigate
whether similar complications are common with SARS-CoV-2 infection as well (Dang et
al., 2020). In a June 2020 case study, Hosier et al. investigated the symptomatology of a
COVID-19 positive patient whose pregnancy was terminated due to severe preeclampsia
that was resulting in critical health conditions. The findings of the study suggested that
the patient’s SARS-CoV-2 infection progressed inflammation in her placenta. Hosier et
al. claimed that it is very possible that the COVID-related hyperinflammation is what
prompted the early onset of preeclampsia. These results were supported by a study
conducted by Beys-da-Silva et al. in March 2021 that concluded that the manifestation of
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SARS-CoV-2 in pregnant patients induces a “preeclampsia-like syndrome” (Beys-daSilva et al., 2021). There are several key implications of these findings: rates of
preeclampsia diagnosis may be higher in pregnant women with SARS-CoV-2 infections
and devastating preeclampsia-like complications are a possible result of SARS-CoV-2
and pregnancy.
While these implications may be disheartening, Ghi et al. conducted a study in
2020 that suggests a more hopeful outcome. Through additional investigation of the
specific physiological and immunological changes that take place during pregnancy, the
authors suggest that changes in expression of specific T-cells might actually allow for
enhanced protection against the cytokine storms commonly associated with SARS-CoV-2
infections (Ghi et al., 2020). The authors describe that the obstetric population is typically
more susceptible to viral
antigens because pregnant
women experience a shift
from T helper type 1 (Th1)
cells to (T helper type 2) Th2
cells dominated immunity as
their Th1 levels are
suppressed during pregnancy.
Th1 cells are typically the first
Figure 2. Comparison of activated RAS pathway
leading to endothelial dysfunction (ED) during
SARS-CoV-2 infection (left) and Preeclampsia
(right; Illi et al., 2021).

line of defense against
intracellular pathogens, so the
suppression of these cells
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largely drives the vulnerability associated with pregnancy. The implications of such an
immunological shift are grim, so Ghi. et al were surprised when they found no indication
of higher morbidity or mortality rates among pregnant versus nonpregnant individuals
(Ghi et al., 2020). In fact, the authors found that COVID-induced pneumonia resulting in
tissue damage was less common in pregnant than nonpregnant patients. With this in
mind, Ghi et al. suggest that pregnant women are more likely to avoid severe cytokine
storms due to their
immunological shift
from Th1 cells,
which stimulate
proinflammatory
cytokines, to Th2
cells, which largely
produce cytokines

Figure 3. The protective effect of pregnancy on the natural
history of Covid-19 infection (Ghi et al., 2020).

with an anti-inflammatory response (Figure 3; Ghi et al., 2020).
Overall, the implications of the previously discussed studies suggest the need for
a more comprehensive understanding of the virus's manifestation in this vulnerable
population. Studies that seek to further investigate the effects of SARS-CoV-2 infection
on pregnancy are crucial in identifying the best ways to optimize treatment and care for
the obstetric population while limiting the adverse effects of the COVID-19 pandemic.
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Seroprevalence of COVID-19 in the Obstetric Population
This study specifically investigates SARS-CoV-2 infections within the obstetric
population through seroprevalence surveys. Seroprevalence surveys, or serosurveys, are
used to study the humoral immune response to viruses from an antibody perspective and
are particularly useful for understanding viruses with asymptomatic spread such as
SARS-CoV-2. Serosurveys allow researchers to analyze the true transmission state of a
virus and track its prevalence over time (Murhekar & Clapham, 2021). In a recent
interview with Dr. Soumya Swaminathan, WHO’s Chief Scientist, Dr. Swaminathan
revealed that seroprevalence studies revealed that 5-10x more people have been exposed
to SARS-CoV-2 than has been indicated by PCR tests. This number increases as high as
40x in some regions (Swaminathan, 2021). However, although these numbers may
heighten the hopes of those suggesting the possibility of herd immunity, Dr.
Swaminathan also explained that serosurvey data also suggests that only about 5-10% of
the population in most regions have antibodies present within their systems – even in
locations that have had the largest outbreaks. Therefore, the vast majority of the globe is
still susceptible to the virus if they are exposed, and herd immunity remains far from an
effective solution at the current state of the pandemic (Swaminathan, 2021).
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Figure 4. Specific antibody response to SARS-CoV-2. The incubation
period of COVID-19 is relatively long and has been reported to be 5-10
d. A specific IgM response is the early antibody response that starts and
peaks within 7 d. IgM continues as long as the acute phase of the
disease continues. Specific IgA and IgG antibodies develop several days
after IgM and do not decrease to undetectable levels and are assumed to
continue lifelong as protective antibodies (Azkur et al., 2020).

Serological surveys are conducted by extracting antibodies from blood specimens.
Functional and neutralizing antibodies that are extracted from serum are called
immunoglobulins and several different classes are typically observed in serosurveys: IgA,
IgG, and IgM (Figure 4). Making up 75-85% of all antibodies in the body, IgGs are the
most common antibodies and are crucial in fighting viral and bacterial infections. IgA
and IgM antibodies make up 10-15% and 5-10% of antibodies in the body respectively.
IgM antibodies present themselves and peak prior to IgA and IgG as they are the first
response to infection (Healthwise Staff, 2020). Additionally, various antibody targets can
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be monitored within the immunoglobulin types. In the analyses of SARS-CoV-2, spike
protein (S), receptor binding domain (RBD), and nucleocapsid protein (N) targets are the
most commonly analyzed (Ortega et al., 2021).
Although IgA, IgG, and IgM have all been identified in COVID serosurveys, only
IgGs were analyzed in this study as the neonatal Fc receptor (FcRn) in the placenta
specifically selects only IgGs for maternal-fetal transfer and therefore they are the most
abundant antibodies present in the collected umbilical cord blood (Jennewein et al.,
2019). Additionally, to narrow the scope of the study, only RBD antibodies were
analyzed as they are less likely to have cross-reactivity with the commonly circulated
HCoVs. Using RBD as an antigen is particularly useful and important for SARS-CoV-2
because it isolates neutralizing antibodies that have been identified as essential to COVID
therapeutics (Min & Sun, 2021). In fact, there is currently an RBD-based COVID vaccine

Figure 5. Graphical representation of the longevity and magnitude of the nAb antibody
response to coronaviruses according to disease severity: (a) antibody response to SARSCoV, MERS, and HCoVs (b) SARS-CoV-2 antibody response (Hamady et al., 2021).
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in phase three clinical trials in China that engages those RBD neutralizing antibodies to
protect against the virus (Yang et al., 2020).
Looking back to SARS-CoV and MERS, serosurveys suggest that antibody titres
to SARS-CoV-2 will likely not maintain high levels as both betacoronaviruses had
undetectably low titres within two years following infection (Figure 5; Hamady et al.,
2021). In a March 2021 study, Hamady et al. expanded on the previous findings of the
antibody course in patients infected with SARS-CoV and MERS and compared it to
recent SARS-CoV-2 antibody data. The authors reported that IgG antibodies reached
their peak titres at ~2-4 months post symptom onset (PSO) for SARS-CoV and ~3 weeks
PSO for MERS. Comparably, the authors found that IgGs for SARS-CoV-2 peaked at
~2-3 PSO, plateau, and began to decline within 2-3 months PSO (Hamady et al., 2021).
Through mathematical modeling, Hamady et al. estimated that IgG levels one-year PSO
reduce to 31% of their levels at 2 weeks PSO. In a similar study published in August
2021, Ortega et al. found that SARS-CoV-2 IgG antibody levels antibody levels peaked
~50 days PSO and remained steady for up to ~230 days PSO whereas IgA and IgM
antibodies peaked within the first month post symptom onset and steadily declined
(Ortega et al., 2021). Although they were unable to find a concrete explanation, the
authors also observed an uptick in IgG antibody levels ~150 days PSO with a constant,
slight increase in levels up to 230 days PSO (Ortega et al., 2021). Both Ortega et al. and
Hamady et al. additionally observed a correlation between the longevity of IgG antibody
responses with increased COVID severity. Hamady et al. found that the majority of study
participants who had severe SARS-CoV-2 infections experienced detectable IgG levels
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one-year PSO whereas 67% of participants with mild symptoms had IgG levels that were
undetectable (Hamady et al., 2021).
Serological surveys can also be used to evaluate how viruses manifest within
particular populations relative to others. In the case of this study, antibodies were
extracted from the umbilical cord blood of a group of pregnant study participants directly
following the delivery of their babies. Isolating cord blood antibodies allows for an
analysis of the IgGs that have been transferred from the mother to the baby through
vertical transmission as umbilical cord blood is t from the neonate rather than the mother.
From this perspective, the various factors that influence a mother’s pregnancy and
COVID course can be used to inform analyses of maternal-fetal transfer and the antibody
abundance of the neonate. To date, there is still a lack of robust knowledge of SARSCoV-2 antibody transfer across the placenta due to the relative newness of the virus.
However, significant progress has been made in the last decade in understanding the
mechanisms that drive the trans-placental transfer and selection of antibodies across the
placenta from the mother to the fetus through the study of other viral antigens. The
findings of these studies have significant implications for how to best navigate SARSCoV-2 infections and vaccinations in the obstetric population.
Dr. Galit Alter, Professor of Immunology and Virology at Harvard Medical
School and group leader at the Ragon Institute of Mass General Hospital, MIT and
Harvard, and her team have reshaped the scope of this field through technology they have
developed in systems serology. Dr. Alter’s first major contribution to the understanding
of the mechanisms behind maternal-fetal antibody transfer involved the selective transfer
of IgGs and the general humoral immune response in women with HIV infections. Along
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with the fascinating implications of the results from this study, Dr. Alter and her team
were able to create comprehensive antibody profiling tools using machine learning
technology and systems serology that allowed them to adapt their programs very quickly
to SARS-CoV-2 in 2020.
In a February 2021 presentation as part of the Howard Hughes Medical Institute’s
speaker series, Dr. Alter explained more about
what she and her team have recently
discovered about placental antibody transfer
generally using their modern technology as
well as early findings from their analysis of
the humoral immune response to SARS-CoV2 and the subsequent vertical transmission.
She described that the taking off point for her
team was largely the fact that the dogma for
placenta-driven antibody transfer was still
wildly incomplete as modern studies continue

Figure 6. Comparison of IgG
concentrations in 46 paired maternalcord sets (Kohler & Farr, 1966).

to find conflicting results that never seem to be comprehensive (Alter, 2021). Using her
antibody profiling technology, Dr. Alter was able to explore the mechanisms behind
placenta-driven antibody selection at a depth that was previously unimaginable.
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Figure 7. Transplacental transfer of molecular and cellular components of maternal
origin: maternal IgG are actively transported across syncytiotrophoblasts by the
neonatal Fc receptor (FcRn). The mechanisms underlying the transfer of IgG across
the placental stroma and fetal endothelium are not fully defined but probably involve
other Fc-gamma (Fcγ) receptors expressed by Hofbauer cells and endothelial cells
(Jennewein et al., 2017).

The first substantial piece of literature declaring a dogma for vertical transmission
was published in the 1960s. The dogma stated that the transfer across the placenta is
highly selective for IgG antibodies, that there is a hierarchy of the IgG subclasses that are
selected for transfer (IgG1 = IgG3 > IgG4 > IgG2), and that maternal and fetal antibody
levels are directly correlated (Figure 6; Kohler & Farr, 1966). This dogma was upheld for
~30 years until a paradigm shift occurred through the findings of various studies in the
1990s that identified the neonatal FcRn, a Fc receptor that is highly expressed on the
syncytiotrophoblasts in the placenta that appeared to play a specific role of transferring
IgG antibodies from the mother to the fetus (Figure 7). Thus, it must be assumed that all
IgGs will be equally represented in the cord blood as the FcRn binds to all IgGs
indiscriminately (Story et al., 1994 and Dickinson et al., 1999). Although the role of the
FcRn in trans-placental transfer of IgGs has been verified, its role as the primary receptor
selecting for transfer across the placenta has been put into question as more recent studies
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have found that certain IgG1s are transferred preferentially to the fetus whereas others are
transferred poorly (Fu et al., 2016). Therefore, Dr. Alter and her team sought to fill in this
gap between the role of the FcRn in IgG transfer and the observed differential transfer of
IgG1s across the placenta.
Dr. Alter and her colleagues began this investigation by looking at the function of
antibodies that were transferred across the placenta following the administration of the
pertussis, or whooping cough, vaccination (DTaP) that the majority of women receive
during their pregnancy. As the DTap is composed of four antigens, Dr. Alter was able to
use those antigens to capture pertussis specific antibodies. The analyses of this
experiment yielded significant results that suggest that the placenta was selectively
filtering antigen specific IgGs based on their function as it was inducing natural killer
(NK) cell activation at distinctively high levels (Jennewein et al., 2019). Dr. Alter and her
team were also able to identify a very significant trend in the preferential transfer of
glycosylated antibodies and suppression of agalactosylated – that is, antibodies have
galactose sugar structures on their backend versus antibodies that do not have galactose
backends respectively. To affirm these results, they performed a monoclonal antibody
experiment including antibodies that had either very short (G0F PG128) or long (G2F
PGT128) galactose structures. Monoclonal antibodies are laboratory-engineered
molecules that serve a similar neutralizing function as the antibody it is emulating. The
findings of this experiment showed that there was increased receptor binding to G2F
PGT128 in the neonatal receptor FcRN as well as FcgRIII, a receptor that largely
regulates NK cell activation (Figure 8A; Jennewein et al., 2019). Ultimately, the results
of these Fc receptor analyses allowed Dr. Alter and her colleagues to claim that antibody
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glycosylation plays a distinct role in the IgGs that are selected by the placenta and
provide robust NK cell protection for the fetus (Figure 8B).

Figure 8. A. Galactosylation Selectively Enhances FcRn, FCGR3 Binding, and NK Cell
Activation. A monoclonal antibody was glycoengineered to either be fully agalactosylated
(G0F) or fully digalactosylated (G2F). The bar graphs show the binding levels of the
glycovariant monoclonal antibody to distinct human Fc-receptors by ELISA. Data are
presented as area under the curve (AUC) of four 5-fold dilutions or AUC of five 2-fold
dilutions (FcRn). Error bars show the SD. B. FcR Expression in the Placenta: The model
depicts the potentially involvement of FcRn and FCGR3A collaboration with the trophoblasts,
on selective antibody capture and subclass and Fc-glycan sieving, aimed at selectively
transferring NK cell-activating antibodies to newborns (Jennewein et al., 2019).
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The COVID-19 pandemic introduces an additional important layer to
understanding trans-placental antibody transfer as viral infections often change the kind
of antibodies that are produced. Previous studies of malaria and HIV have also shown
that the quality of antibody transfer is reduced during active infection which results in the
transfer of fewer antibodies (Alter, 2021). With Dr. Alter as the experiment leader, Ateyo
et al. investigated SARS-CoV-2 antibody transfer through an investigation of 56
maternal-fetal pairs (34 pregnant healthy controls and 22 pregnant patients who were
COVID+ in the third trimester). The authors found that transfer of SARS-CoV-2 antigens
(RBD, S, and N in the COVID+ patients to the fetuses was neutral if not decreased – the
opposite of what would be expected in healthy individuals. This was particularly notable
as the COVID+ patients were still transferring increased levels of antibodies to fluspecific antigens, so there was something specifically affecting the transfer of SARSCoV-2 IgGs (Ateyo et al, 2021).

Figure 9. The effect of time on SARS-CoV-2-specific antibody transfer: The dot plots
show the relative IgG titer for RBD, S, N and HA in maternal plasma and cord blood
in which the mother was infected during the second or third trimester. Lines connect
mother:cord dyads. The data is represented as the absorbance at 450 nm subtracted by
the reference absorbance read at 570 nm. The data was background corrected using
plasma that was negative for SARS-CoV-2 antibodies (Ateyo et al., 2021).
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To investigate whether this decrease in COVID antibodies was consistent across
mothers with second trimester SARS-CoV-2 infections as well, the authors introduced
additional cohorts of second (n = 29) and third (n = 28) trimester COVID+ patients.
Ateyo et al. found that the drastic changes in SARS-CoV-2 antibody transfer was not
present in second trimester infections and higher antibody levels were noted (Figure 9).
Therefore, the authors suggest that the shift in antibody profiles and subsequent transfer
observed in the third trimester is influenced by COVID-induced inflammation. These
changes are not present in second trimester infections because the inflammation
associated with active infection has resolved, so the placenta is able to revert back to
healthy function for the entirety of the third trimester when vertical transmission is most
active (Ateyo et al., 2021). These results are significant as they indicate, contrary to most
other viral infections, that SARS-COV-2 vaccination during the second trimester will
likely lead to the most effective outcomes.
Further investigation of the mechanisms of maternal-fetal transfer for mothers
with third trimester infection suggested that glycosylation would play a significant role in
SARS-CoV-2 antibody response as well. Ateyo et al. found that the presence of fucose
sugars on the glycosylated tails was a large determinant of which antibodies were
transferred to the baby – antibodies that lacked fucose were selectively transferred and
antibodies with fucose present were retained (Ateyo et al, 2021). Dr. Alter suggests that
this change in selection is likely because afucosylated antibodies are better at binding to
Fc receptors including the neonatal receptor. This finding suggests even greater
implications as fucose plays a key role in NK cell activation through the same FcgRII
receptor (Alter, 2021). In summary, Ateyo et al. explain, infection of SARS-CoV-2 in the
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third trimester causes the antibodies that are produced to have different glycan profiles.
This, in turn, results in the augmentation of specific Fc receptors associated with NK cell
activation such as FcgRIII in the placenta so that, while there are less antibodies present
in the cord overall, the antibodies that the fetus receives have the highest capacity for
protection through a robust recruitment of NK cell activity.

Research Plan
Using antibody data extracted from specimens collected at the UMass Memorial
Medical Center and UMass Chan Medical School, this thesis will conduct further
analyses based on the early studies of SARS-CoV-2 in the obstetric population discussed
above. After cord blood samples are compared to positive and negative controls, the
interaction between preeclampsia and SARS-CoV-2 will be explored from an antibody
perspective. Next, an investigation of seropositivity and PCR status led to analyses of
antibody levels and serostatus relative to trimester of SARS-CoV-2 infection.
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Methods
Study Populations
Three populations were included in this study: 144 pregnant women from the
UMass Memorial Medical Center (UMMC) labor and delivery unit, 49 COVID+
hospitalized non-pregnant women from the UMass Chan Medical School (UMCMS)
hospital, and 21 healthy female controls whose samples were collected prior to the
pandemic.
Obstetric Population: As part of the CARES Study, the pregnant population observed in
this experiment were collected at UMMC in the labor and delivery unit from April 2020
to August 2021. There were over 200 patients approached for the study and a total of 144
patients consented to participate in the study. Among the 144 patients enrolled, antibody
data was available for 84 patients. The sample size of this dataset and within specific
analyses was limited due to missing information across the various metrics examined
(Figure 10). As such, racial and ethnic demographic information was only available for
80 of the 84 patients, but the distribution was as follows: 47.5% White/Caucasian, 32.5%
Hispanic/Latina, 13.75% Black/African American, and 6.25% Asian/Asian American
(Figure 11). These patients ranged from 21 years of age to 44 years of age. The labor and
delivery unit at UMMC, is the main unit in the area that has the capacity to manage highrisk pregnancies. Therefore, the proportion of the patients with high-risk conditions such
as preeclampsia at UMMC is greater than is representative of the obstetric population as a
whole (0.6-1.2%; Society for Maternal-Fetal Medicine, 2013). Of the 84 CARES patients
included in the study, 28 of them, or ~33%, were diagnosed with preeclampsia. Finally,
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universal screening was implemented in the UMMC labor and delivery unit for the
duration of the CARES study.

Figure 10. CARES Study flow chart including the sample sizes of all conducted
analyses.

Nonpregnant Population: Originally collected as part of the Consolidated COVID-19
Clinical and Observational Pathogenesis and Epidemiology (COVID-COPE) Study, the
non-pregnant population consists of hospitalized COVID-19 patients and serves as a
positive control relative to the pregnant population in this study. Blood samples from 49
symptomatic women were collected between April 2020 - June 2020 at UMMC. The
demographics of the group was less diverse than the pregnant group: 71%
White/Caucasian, 14.3% Hispanic/Latino, 10.2% Black/African American, and 8.16%
Asian/Asian American (Figure 11). As available specimens for women of reproductive
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age were limited within this population, specimens from women of all ages were
analyzed which resulted in an age range of 19-97 years old. The median age of the nonpregnant group was 75 years old.

Figure 11. Racial and ethnic demographics of three study populations: CARES
pregnant women (n = 80), nonpregnant hospitalized women (n = 49), and healthy
women whose samples were collected prior to the pandemic (n =27).

Pre-Pandemic Population: The pre-pandemic population included 21 healthy women
whose preserved samples were primarily collected at UMMC in 2016, but the collection
dates ranged from July 2007-August 2019. This population was the least racially and
ethnically diverse group with 88.8% of the population identifying as White/Caucasian,
7.4% of the population being Black/African American, and the last 3.7% being
Asian/Asian American (Figure 11). All of the women included were 18+ years of age
with the oldest age reported as 66 years.
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Experimental Timeline
As SARS-CoV-2 is constantly evolving and two new variants, as well several
vaccines, have emerged since the beginning of the CARES study, it is important to situate
our study population within the timeline of variants and development of the vaccine. The
majority of the data was collected prior to the establishment of the delta variant in the
United States. As the delta variant was confirmed to be present in the United States in
May 2021, it is likely that the Delta variant is only possibly represented in the last two
months of the fifteen-month study. Similarly, SARS-CoV-2 vaccines were not made
available to the public beyond healthcare workers and the elderly until early-mid 2021
across the United States. Therefore, none of the nonpregnant COVID patients whose
samples were collected between April – June 2020 were vaccinated. With the additional
uncertainty of the vaccine in pregnant women as the obstetric population was excluded
from experimental trials, only four of the CARES women with antibody data available
had received a vaccine prior to delivery even though samples were collected through
August 2021. Finally, there were actively used treatment options for SARS-CoV-2 at the
time of the study, but none of the participants received any COVID-specific treatments
beyond medications for symptom management.

Laboratory Analyses
SARS-CoV-2 Enzyme-Linked ImmunoSorbent Assay (ELISA): The SARS-CoV-2
ELISA assay developed at the Ragon Institute as previously published (PMID:
32780998) was implemented in the Moormann lab at UMCMS. Receptor-binding domain
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(RBD), Spike trimer subunits (S), and nucleocapsid protein (N) SARS-CoV-2 antigens
utilized in the study were provided by MassBiologics in Mattapan, MA
(PMID:32826914). SARS-CoV2 RBD antigens provided by the Ragon Institute in
Cambridge, MA were also used. Briefly, 384-well MaxiSorp plates (Thermo-Fisher,
Waltham, MA) were coated for 30 minutes at room temperature with 50 µL of antigen
diluted in coating buffer at the final concentration of 1 µg/mL for N; 0.5 µg/mL for RBD;
2.5 µg/mL for S; or human plasma from a healthy donor at 1:20,000 dilution as HRP
control. Plates were washed three times with wash buffer using the AQUAMax™ 2000
plate washer (Molecular Devices, San Jose, CA) and then blocked for 30 minutes at room
temperature in 100 µL of blocking buffer. Plates were washed three times and 50 µL of
samples diluted in 140 mM of NaCl, 50 mM of Tris-HCl, 0.05% of Tween and 1% BSA,
were added (dilution of 1:100), as well as plate internal controls composed of High,
Medium, Low (based on RBD-specific IgG) and Pre-pandemic pool in triplicate. Plates
were sealed and incubated at 37°C for 30 minutes, then washed five times. Next, 50 µL
of diluted HRP conjugated anti-human antibody was added to each well: 1:25000 for
anti-IgG and anti-IgM; 1:10000 for anti-IgA (HRP-anti human antibodies from Bethyl
Laboratories, Montgomery, Texas). The plate was incubated in the dark at room
temperature for 30 minutes and then washed five times. Next, 40 µL of 1-Step Ultra
TMB peroxidase substrate (Thermo-Fisher, Waltham, MA) was added to each well and
developed at room temperature (3 minutes for IgG; 5 minutes for IgA and IgM). The
reaction was stopped with 40 µL of 1M Sulfuric Acid (EMD Millipore, Burlington, MA).
Absorbance was measured using an “End-Point'' protocol at 450 nm and 570 nm on the
SpectraMax iD5 ELISA plate reader (Molecular Devices, San Jose, CA) using the
SoftMax Pro software version 7.1 (Molecular Devices, San Jose, CA). The 570 nm OD
was subtracted from the 450 nm OD for the final OD value.
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Standard Curves: CR3022 (PMID: 32245784) dilution curves were used to assess RBD
and S proteins. The antibody (IgG, IgA or IgM) was diluted to a concentration of 2.5
μg/ml in the dilution buffer and a 12 two-fold serial dilution curve was generated in
triplicate and plated. A pool of plasma from SARS-CoV-2 hospitalized patients (n=15)
was used as a standard curve for the N protein with a 12 two-fold serial dilution. Finally,
the 4-parameter logistic standard curve generated by the SoftMax Pro software was used

Statistical Analyses
RBD IgG OD data was observed across various clinical factors and served as the
primary dependent variable in the analyses of this experiment. To account for the limited
sample sizes in each of the independent groups, only univariate analyses were used in this
project. Beyond one Chi-squared test of independence, all of the parametric tests used in
this experiment (ANOVAs and t-tests) have the following assumptions: random
sampling, normally distributed data, and equal variances across factors. Random
sampling was assumed for all of the included data and normality and homoscedasticity
were tested using Shaprio-Wilk tests and Levene’s tests respectively. The Shapiro-Wilk
tests found that none of the raw antibody data was normally distributed with substantial
right skew present. Therefore, a common logarithm transformation was applied to all of
the antibody data upon which several of the study groups properly fit a normal
distribution.
Analysis 1 – Nonpregnant and Pre-Pandemic Comparison (Figure 12): The first analysis
investigated RBD IgG levels across the three study populations. A one-way ANOVA was
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determined to be the ideal parametric test because the independent variable, patient
population status, was categorical and included three, non-repeated factors and the
objective was to compare the central tendency value of the dependent variable (RBD IgG
levels) for each group. Although the log transformation decreased the extent of the right
skew, the RBD IgG data for all three groups still did not fit a normal distribution.
Therefore, a Kruskal-Wallis (K-W) test, the non-parametric equivalent of an ANOVA
was performed. The ANOVA was followed up with pairwise Wilcoxon analyses with an
applied Bonferroni correction to adjust for alpha inflation were conducted.

Analysis 2 – CARES Preeclampsia and COVID Comparison (Figure 13): The second
analysis sought to determine if preeclampsia status would influence antibody levels
transferred to the fetus. Similar to the first analysis, a one-way ANOVA was chosen
because the independent variable, patient preeclampsia and COVID status in this case,
was categorical and included four, non-repeated factors. The goal of this analysis was
also to determine if there was a difference in the central tendency value of the antibody
levels for each group. Regardless of the log transformation, the IgG data was not
normally distributed, so another K-W test was conducted. Bonferroni corrected Wilcoxon
pairwise tests were then performed.

Analysis 3 – COVID PCR and Serostatus Status (Figure 14): To further investigate the
relationship between COVID PCR status and serostatus, this analysis used IgG antibody
levels in CARES patients to investigate rates of seropositivity relative to patient PCR
status. The independent variable in this analysis was COVID PCR status – a categorical
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variable with two, non-repeated factors. Therefore, a Wilcoxon test, the non-parametric
equivalent of a t-test, was performed because the PCR status data did not meet the
assumption of a normal distribution.

Analysis 4 – COVID Serostatus and PCR Status by Trimester (Figure 15): Given the
results of the previous analysis, the fourth analysis investigated the subgroup of CARES
patients who were PCR positive according to their seropositivity and trimester of
infection. First trimester infections were excluded from this analysis due to the low
sample size available (n = 3) and relatively low maternal-fetal antibody transfer in the
first trimester found in previous studies (Arora et al., 2017 and Ateyo et al., 2021). As
both serostatus and trimester of infection were categorical variables, a Chi-squared test of
independence was performed to determine difference between the groups. All of the
frequency values included were greater than 5, so the Yates correction was removed prior
to running the test.

Analysis 5 – Trimesters of SARS-CoV-2 Infection (Figure 16): The last analysis further
investigated the influence of trimesters of SARS-CoV-2 infection on antibody levels in
the cord and sought to directly compare mean IgG levels between the second and third
trimesters. Application of the log transformation was successful in creating normally
distributed dataset and a Levene’s test confirmed that the data was homoscedastic. As the
first trimester data was excluded, there were only two independent variables, and a t-test
was performed.

Rose 37

Supplemental Analyses: RBD IgG OD levels were also evaluated across the
demographics of race/ethnicity, and age. Antibody data for race/ethnicity was normally
distributed and possessed homogenous variances, so an ANOVA test was performed
(Supplemental Figure 1). The antibody data for age was not normally distributed, so a
Kruskal-Wallis test was conducted (Supplemental Figure 2). IgG antibody differences
were also explored across the sex of the neonate and symptomology at COVID diagnosis
as previous studies have found trends of lower antibody levels in male neonates and
patients who have pre-symptomatic or asymptomatic SARS-CoV infection (Bordt et al.,
2021 and Hamady et al., 2021). Antibody data for the influence of neonate sex was not
normally distributed, so a nonparametric Wilcoxon test was used (Supplemental Figure
3). The symptomology antibody data fit a normal distribution, so a parametric t-test was
performed (Supplemental Figures 4).

Thresholds for Seropositivity
Two statistically relevant cut offs were considered and applied to the RBD IgG
OD data: Maximum Specificity (Max Spec.) and 3 Standard Deviation (3 SD). The max
spec. cut off was simply a representation of the largest value within the pre-pandemic
control population. With this cut off, all of the negative controls would fall below the cut
off which ultimately maximizes the specificity of the cut off value. The 3SD cut off, the
standard for clinically validated diagnostic tests, is a representation of the value three
standard deviations above the mean of the negative pre-pandemic control population. As
is suggested by their names, the 3SD cut off is less specific than the max spec. cut off,
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but it provides the benefit of a greater sensitivity. Ultimately, the three SD cut off was the
main threshold used in this experiment as sensitivity was prioritized.

Relevant Clinical Definitions
COVID Status – UMMC: A patient was considered to be COVID positive in the UMMC
labor and delivery unit if they had a positive PCR test result.
Serostatus: Seropositivity was determined by whether a patient’s IgG levels fell above or
below the 3SD cut off. A patient was considered to be seropositive for SARS-CoV-2 if
their RBD IgG OD antibody levels were higher than 0.484, the 3 SD cut off.
Preeclampsia Status: A patient was considered to have preeclampsia at UMMC if they
met the following criteria: blood pressure above 140/90 and urine protein levels of 0.3
grams or greater in 24-hours. Severe features can be developed if metrics rise (see
Supplemental Figure 1) with or without proteinuria, which commonly requires prompt
delivery regardless of the patient’s gestational age.

Ethical Approval
CARES Study IRB approval: Study participants were approached and consented in the
Massachusetts Memorial Medical Center (UMass Memorial) labor and delivery unit in
Worcester, MA between April 2020 and August 2021. The Institutional Review Board
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(IRB) at the UMCMS COVID-19 Analysis on Perinatal Specimens Related to Exposure
(CARES) Study (H00020140).
COVID-COPE Study IRB approval: Study participants were enrolled at the University of
Massachusetts Chan Medical School (UMass Chan) and the Massachusetts Memorial
Medical Center (UMass Memorial) in Worcester, MA between April and August of 2020
under the Institutional Review Board (IRB) approved Consolidated COVID-19 Clinical
and Observational Pathogenesis and Epidemiology (COVID-COPE) Study Protocol
(H00020145). RTW included graduate and medical students and permission was obtained
from the Students as Research Subjects (SAS) Ad Hoc Advisory Committee, a governing
body which aims to protect the rights and interests of students at UMass Chan.
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Results
Comparison between non-pregnant women and cord blood antibody levels
The purpose of the first analysis was to investigate RBD IgG levels across the
three study populations. As expected, there was a significant difference between median
RBD IgG OD levels extracted from the blood samples from healthy women prior to the

Figure 12. Levels of RBD IgG OD across Healthy Pre-pandemic (n = 21), CARES
Cord Blood (n = 84), and COVID+ Nonpregnant (n = 51) groups.
pandemic, hospitalized nonpregnant women, and from umbilical cord of pregnant women
part of the CARES study (KW X22 = 41.857, p = 8.145x10-10). While the median RBD
IgG OD level of the pre-pandemic group was statistically lower than the CARES (p =
3.10x10-8) and nonpregnant (p = 1.20x10-9) COVID-19 patients, there was not a
significant difference between median RBD IgG OD levels of the CARES and
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nonpregnant groups (p = 0.580). The percent seropositive in each group using the 3 SD
cutoff is as follows: 0% in the pre-pandemic group, ~39% in the nonpregnant group, and
~40% in the CARES group.

CARES Preeclampsia and COVID PCR Comparisons
Given parallels drawn between the inflammatory responses of SARS-CoV-2 and
preeclampsia, preeclampsia status was included in our serological analysis of SARSCoV-2. In order to determine if antibody levels transferred to the infant differed by PCR
positivity or preeclampsia diagnosis of the mother, we stratified the pregnant women by
these variables within the CARES study population. A significant difference between the
RBD IgG OD levels of CARES pregnant women of varying preeclampsia and PCR
COVID statuses* was observed (KW X23 =11.289, p = 0.0103). There was a distinct
trend towards significant difference between the preeclampsia -/COVID + group and the
preeclampsia -/COVID - group (0.078) as well as the preeclampsia -/COVID + group and
the preeclampsia +/COVID - (p = 0.114). Preeclampsia was present in ~33% of the
CARES patients (28/84) and only ~32% of those that were preeclampsia+ were also
COVID+ (9/28). Therefore, there also did not appear to be a significant connection
between COVID positivity and preeclampsia.
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Figure 13. RBD IgG OD in neonates delivered by women across the four CARES
categories according to preeclampsia and covid statuses: preeclampsia -/COVID (n = 14), preeclampsia -/COVID + (n = 42), preeclampsia +/COVID - (n = 19),
and preeclampsia +/COVID + (n = 9).
*In this analysis, the antibodies extracted from the cord blood served as a
surrogate of the mother’s serostatus.

COVID PCR and Serostatus Status
The objective of this analysis was to compare IgG antibody levels in CARES
patients according to COVD PCR positivity and investigate rates of seropositivity
relative to PCR status. As expected, there was a significant difference in median RBD
IgG OD levels of neonates whose mothers were SARS-CoV-2 PCR positive versus
negative (W = 1190, p = 0.00144). The proportion of seropositive patients in the PCR
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negative and PCR positive groups is ~21% and ~53% respectively. Mothers who were
PCR negative but had antibodies most likely had infections prior to becoming pregnant.

Figure 14. RBD IgG OD levels in neonates whose mothers were
determined to be positive (n = 51) and negative (n = 33) for COVID through
a SARS-CoV-2 PCR test.

COVID Serostatus and PCR Status by Trimester
Given the number of CARES patients who were PCR+ and seronegative, we
sought to identify whether there was a correlation between serostatus in this
subpopulation and the trimester in which they were exposed to SARS-CoV-2. Across
patients who tested positive for SARS-CoV-2 using a PCR test and had trimester of
infection data available, 46% of their neonates were considered to be seronegative and
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54% were considered to be seropositive using the 3SD cutoff. Within those subgroups,
~56% of the seronegative group had mothers who had 3rd trimester COVID infections
and ~67% of the seropositive group had mothers who had 2nd trimester COVID
infections (Figure 15A&B). Trimester of infection was found to significantly influence
the seropositivity of neonates whose mothers were PCR positive for COVID (X 2 = 3.43,
p-value = 0.0635).

A.

B.

Figure 15. Trimester of COVID infection distribution across mothers who were PCR
positive, but whose neonates were considered to be seronegative (A) versus mothers who
were PCR positive and whose neonates were considered to be seropositive(B).
Seropositivity was determined using the 3SD cutoff.

Rose 45

Serostatus by Trimesters of SARS-CoV-2 Infection
Additional analyses on trimester of infection affirmed the previous results and
found that there was a significant difference between mean RBD IgG OD levels in
neonates whose mothers contracted SARS-CoV-2 in the second trimester versus the third
trimester (Figure 16; t45 = 2.765, p = 0.00822). On average, mothers with second
trimester COVID infections transferred the highest levels of RBD IgG OD to their babies.
Mean antibody levels were ~48% lower in neonates whose mothers tested positive in the
third trimester (x̄ =0.639) than mean levels in neonates whose moms had second semester
infections (x̄ = 1.232).

Figure 16. RBD IgG OD levels in neonates whose mothers contracted in the
second trimester (n = 25) and third trimester (n = 22).
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Discussion
Key Findings
In this study, the impact of SARS-CoV-2 during pregnancy was investigated
through various antibody driven analyses. The major findings of this paper suggest a
more positive outlook for the obstetric population than may have been originally assumed
and provide insight into optimizing COVID vaccines during pregnancy. The first analysis
found that there was no striking difference between the RBD IgG levels produced in the
nonpregnant PCR+ individuals and the levels in the CARES cord blood (Figure 12).
These results suggest that fetuses are actively receiving comparable amounts of
antibodies relative to individuals who contracted COVID themselves.
Further analysis of antibody levels across CARES patients according to their
COVID PCR and preeclampsia diagnosis found that preeclampsia status was not
associated with the levels of RBD IgG transfer to the fetus (Figure 13). This is evident as
the antibody levels in COVID PCR+ moms with diagnosed preeclampsia were not
significantly different than those without preeclampsia. PCR- CARES patients have
either never been exposed to SARS-CoV-2 or they were remotely infected prior to
becoming pregnant. Therefore, if higher rates of seropositivity were detected in PCR patients with a preeclampsia diagnosis, there would be a possible link between
preeclampsia and any residual effects of previous infection. Overall, it appears that
production and maternal-fetal antibody transfer is not significantly influenced by
preeclampsia infections regardless of the strong associations found between the two
conditions.
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Furthermore, investigation of seropositivity in the COVID PCR+ CARES patients
found that there was a strong correlation between trimester of maternal SARS-CoV-2
infection and IgG antibody levels present in the neonate with significantly highest RBD
IgG levels in the cord after second trimester infections (Figure 15). These results were
affirmed in trimester specific analysis of all CARES patients (Figure 16). While these
findings stand out against results for other viral antigens, the higher IgG levels found in
the cord of mothers with second trimester infections were expected and are consistent
with recent literature specific to SARS-CoV-2 trans-placental antibody transfer and fetal
RBD IgG levels (Ateyo et al., 2021). As Dr. Galit Alter detailed in her presentation,
antibody production and maternal-transfer are drastically shifted in the third trimester
infections which is likely due to the inflammation induced by active COVID-19 during
the phase of pregnancy in which the most maternal-fetal transfer should take place. As
was mentioned in the introduction, the results of this analysis have significant
implications for the optimal COVID vaccination time during pregnancy. According to the
results of this thesis, which are supported by significant literature, maternal-fetal transfer
of SARS-CoV-2 antibodies across the placenta is most effective with second trimester
infections and therefore medical professionals should seriously consider second trimester
vaccination administration.

Misclassification Bias for SARS-CoV-2
As this paper was conducted using cross-sectional sampling, as opposed to
repeated measures, it is important to discuss the possibility of misclassification due to the
time dependent nature of SARS-CoV-2 manifestation in humans. The patients in this
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study were classified according to two main factors: PCR status and serostatus. As the
main diagnostic test used for SARS-CoV-2 throughout the course of the pandemic, PCR
tests are highly effective tools that are used to detect viral RNA in the body. PCR tests
are highly accurate in detecting active SARS-CoV-2 infections in pre-symptomatic,
asymptomatic, and symptomatic individuals, but it is not a perfect diagnostic tool as it is
dependent on the timing relative to exposure to the virus. In a 2021 study of SARS-CoV2 PCR testing, Rabaan et al. found that time of specimen sampling along with the
progression of the disease in the individual play a significant role in the effectiveness of
PCR testing as a diagnostic tool (Rabaan et al., 2021). Since the disease progression and
duration of viral shedding of SARS-CoV-2 is different for all people exposed to the virus,
there is a high potential for misclassification of PCR status if patients are only tested once
as was true of the CARES patients. For instance, it is possible that a CARES patient had
asymptomatic COVID during their pregnancy, but their viral load declined to the point of
being undetectable by the time they received their next PCR test resulting in a
misclassification. It is also possible to have false negative results from PCR tests if the
sample is collected before the viral load accumulates (Böger et al., 2021). Recent studies
have found that peak viral load typically coincides with symptom onset and that viral
kinetics can be influenced by factors such as disease severity, the presence of symptoms,
and age (Néant et al., 2021 and Liu et al, 2020b).
Misclassification of serostatus is also possible. Limitations in classification of
CARES patients according to serostatus would likely be the result of one of two reasons:
the timing of collection as antibodies propagate and wane at slightly different rates across
patients, or the fact that some people simply produce little to no antibodies. Similar to the
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limitations of PCR classification, it is possible to sample patients too early or too late. A
PCR+ CARES patient could have been classified as seronegative if their cord blood
samples were collected prior to significant antibody production – this is possible for
patients with third trimester infections. Conversely, patients who contracted COVID in
the second trimester might have already experienced antibody waning to the extent of
seronegative classification – especially considering previous studies that identified peak
antibody levels at ~50 days PSO (Ortega et al., 2021). In a recent study of SARS-CoV-2
using convalescent plasma, Klein et al., supervised by Dr. Aaron Tobian at Johns
Hopkins University, found that ~20% of the samples did not produce enough antibodies
to be detectable. Although the exact mechanisms are unknown, these results support the
hypothesis that SARS-CoV-2 is actively attempting to shut down antibody responses to
infection (Klein et al., 2020, Kaneko et al., 2020, and Alter et al., 2021).

Limitations
There were several key limitations to this study. First, the sample size of patients
with antibody data was smaller than was originally intended. As was illustrated in the
experimental flowchart, the CARES study originally included 144 consented patients, but
antibody data was only extracted from the cord serum of 84 of them. This was likely due
to various complications such as insufficient amounts of blood collected, participation
lost to a critical delivery, or issues resulting from specimen transfer across campuses. By
effectively cutting the sample size of the study nearly in half, the scope of possible
analyses was limited due to issues of statistical power. The lack of normally distributed
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data can also be attributed to the low sample sizes, at least partially, through the central
limit theorem.
Secondly, mother-fetus dyads were not included in this study as blood samples
were only currently available for the umbilical cord blood and not maternal blood. This
prevented us from being able to make claims about the actual quality of vertical
transmission observed like Dr. Alter’s studies since the cord blood simply reflects the
serostatus of the baby, leaving a gap of knowledge about the maternal serostatus.
As mentioned above, this thesis was also limited by the cross-sectional nature of
the experiential model. While it was not possible in this experiment, a solution to these
classification limitations would be to conduct repeated measures experiments. Access to
multiple measures for each CARES participant would have helped account for any
possible misclassifications as a result of sampling time.
Finally, the lack of diversity present in the patient population of this study limits
the scope by which we can make suggestions based on the data – particularly in the
nonpregnant and pre-pandemic populations. Given the low sample sizes representing
patients of color in the nonpregnant and pre-pandemic populations, differences in race
were not able to be reasonably tested. Thankfully, the primary dataset investigated in this
study was the CARES study which was the most diverse and more representative of the
U.S. and Massachusetts populations. Regardless, studies further representing the critical
topics discussed in this paper in communities of color is essential in ensuring that
healthcare workers are providing the most inclusive and best care to all of their patients.
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COVID-19 Pandemic Updates
Since the conclusion of data collection for this study, SARS-CoV-2 has continued
to evolve, and significant progress has been made in vaccine development and roll out
across the globe. Various forms of treatment intervention have also been approved.
Five main variants of SARS-CoV-2 have been designated as a variant of concern
(VOC) by the WHO since the beginning of the COVID-19 pandemic: alpha, beta,
gamma, delta, omicron (Figure 17). According to WHO, a variant is designated a VOC if
it increases transmissibility, increases virulence, and/or decreases the effectiveness of
diagnostics, vaccines, or treatments (WHO, 2021c). As disease transmission appears to
be increasing with each new variant, early studies on the most recent omicron variant
have hopeful implications for clinical outcomes associated with the variant. In a
preliminary study through the Kaiser Permanente health system, Lewnard et al. found
that the mortality and ICU admission rates associated with the omicron variant are
approximately ~91% and ~74% lower than the delta variant (Lewnard et al., 2022).
Furthermore, in a report published on January 8th, 2022, the CDC announced omicron as
the dominant variant and estimated that ~98.3% of COVID cases in the U.S. were the
omicron variant (CDC, 2021a). While the initial findings on the omicron variant suggest
less deadly clinical outcomes, the increased transmission is causing U.S. case numbers to
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peak and straining ICU capacity. Given the trajectory of SARS-CoV-2 thus far, it is
highly likely that there will be more variants to come.

Figure 17. WHO-designated SARS-CoV-2 variants of concern (WHO, 2021c).

Along with the emergence of new variants, various vaccines have been developed
across the globe. In the U.S., three primary vaccines have been approved for
administration with striking effectiveness: Pfizer (BioNTech - BNT162b2), Moderna
(NIAID - mRNA-1273), and Johnson & Johnson (J&J; Janssen Pharmaceutical
Companies - JNJ-78436735). The Pfizer and Moderna vaccines are both mRNA-based
vaccines that have efficacy rates of >90% after two administered doses. The J&J vaccine
is a viral vector vaccine that only requires one dose, but is less effective at preventing the
virus with an efficacy rate of ~66% (CDC, 2021d). To date, most studies on vaccine
efficacy in pregnant women have included only the Pfizer and Moderna vaccines with
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great outcomes, although viral vector vaccines such as J&J have been previously
administered to pregnant women during the Ebola outbreak without any adverse
outcomes (CDC, 2021b). As vertical transmission is typically most effective in the third
trimester, the majority of early vaccine trials in the obstetric population only included
pregnant women vaccinated in the third trimester (Dagan et al., 2021). However, the
results of this study were supported in a more recently published study of the Pfizer
vaccine: Kugelman et al. found that vaccination in the second trimester of pregnancy
induced a robust humoral response that is sustained throughout the pregnancy and
provided the mother and fetus with prolonged safety against SARS-CoV-2 (Kugelman et
al., 2022).
Although they have yet to be widely implemented, several treatments for SARSCoV-2 have become available. Monoclonal antibodies, such as those used in Dr. Alter’s
study of SARS-CoV-2 antibody transfer, have been found to successfully prevent severe
or deadly COVID-19. In November 2020, a COVID monoclonal antibody product called
REGEN-COV was approved by the U.S. Food and Drug Administration (FDA) for
emergency use for treatment of COVID in high-risk patients (U.S. FDA, 2021). It is
specifically intended to be used after exposure to SARS-CoV-2 to prevent mild-tomoderate cases from progressing to severe COVID. REGEN-COV contains two SARSCoV-2 monoclonal antibodies, casirivimab and imdevimab, that are capable of reducing
the viral load of SARS-CoV-2 and have been found to decrease the likelihood of
hospitalization or death by ~70% (Mayer et al., 2021). As is true for vaccine trials,
pregnant women are excluded from testing on treatments such as REGEN-COV.
However, since the FDA officially considered pregnancy as a high-risk criterion for
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REGEN-COV in May 2021, several small-scale studies have found that the product
yields the same promising results in pregnant women as in the test populations without
any complications (Hirshberg et al., 2021 and Mayer et al., 2021). While COVID
vaccines have been found to be effective in vertical transmission of antibodies in both the
second and third trimesters, monoclonal antibody treatments could provide alternative
defenses against severe SARS-CoV-2 infections – particularly unvaccinated mothers
(Mayer et al., 2021). While the effects of monoclonal antibodies such as casirivimab and
imdevimab have yet to be widely tested in pregnant women, the possibility that they
provide the obstetric population is immense.
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Supplemental Figures

Supplemental Figure 1. RBD IgG OD levels across pregnant women of various races
and ethnicities: Asian/Asian American (n = 5), Black/African American/African (n =
11), Hispanic/Latina (n = 26), and White/Caucasian (n = 38). All patients who identified
within the Asian/Asian American, Black/African American/African, and
White/Caucasian groups identified themselves as not being Hispanic/Latina.

Supplemental Figure 2. RBD IgG OD levels of neonates delivered from women of
various age groups between 21-44: 21-26 (n = 19), 27-32 (n = 30), 33-38 (n = 24) and
39-44 (n = 6).
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Supplemental Figure 3. Median RBD IgG OD levels in female (n = 47)
versus male (n = 37) neonates

Supplemental Figure 4. RBD IgG OD levels in neonates whose mothers were
asymptomatic (n = 7) and symptomatic (n = 43) at the time of their COVID
diagnosis.
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